Dow Down0.25% Nasdaq Down0.26%

ChemoCentryx, Inc. (CCXI)

5.03 Down 0.07(1.37%) 4:00PM EDT
ProfileGet Profile for:
ChemoCentryx, Inc.
850 Maude Avenue
Mountain View, CA 94043
United States - Map
Phone: 650-210-2900
Fax: 650-210-2910

Index Membership:N/A
Full Time Employees:60

Business Summary 

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe Crohn’s disease; CCX140 that is in Phase II clinical trial for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company’s drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated renal vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for liver diseases. The company was founded in 1997 and is headquartered in Mountain View, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on ChemoCentryx, Inc.

Corporate Governance 
ChemoCentryx, Inc.’s ISS Governance QuickScore as of Aug 1, 2014 is 9. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 8; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Thomas J. Schall Ph.D., 55
Founder, Chairman, Chief Exec. Officer and Pres
Ms. Susan M. Kanaya , 51
Chief Financial Officer, Principal Accounting Officer, Sr. VP of Fin. and Sec.
Dr. Petrus J. Bekker M.D., Ph.D., 54
Sr. VP Medical & Clinical Affairs
Dr. Markus J. Cappel Ph.D., 53
Chief Bus. Officer and Treasurer
Dr. Anne-Marie Duliege M.D., M.S., 55
Chief of Strategic Devel., Head of Immuno-Oncology and Exec. VP
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders